Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intratumoral Gene Mediated Cytotoxic Immunotherapy (GMCI) For Resectable Non-Small Cell Lung Cancer

NCT03131037 is registered in ClinicalTrials.gov with Candel Therapeutics, Inc. as lead sponsor.

NCT NCT03131037
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03131037 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intratumoral Gene Mediated Cytotoxic Immunotherapy (GMCI) For Resectable Non-Small Cell Lung Cancer
Lead sponsor
Candel Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
May 4, 2017
Completion date
September 20, 2023
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer